Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market, 2021-2030.”
The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:
• A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
• Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
• A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
• A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
• A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
• A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
• An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
• A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
• An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
• An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
• A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
• A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
• A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
• A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
Request for Customization: https://www.rootsanalysis.com/reports/250/request-customization.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Commonly Outsourced Business Operations
• Active Pharmaceutical Ingredients (API)
• Finished Dosage Formulations (FDF)
Types of Expression System
• Mammalian
• Microbial
• Others
Company Size
• Small
• Mid-Sized
• Large and Very Large
Scale of Operation
• Preclinical
• Clinical
• Commercial
Key Geographical Region
• North America
• Europe
• Asia-Pacific
• Rest of the World
The report also features detailed transcripts of discussions held with the following experts:
• Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
• Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
• Christian Bailly, Director of CDMO, Pierre Fabre
• Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
• David C Cunningham, Director Corporate Development, Goodwin Biotechnology
• Dietmar Katinger, Chief Executive Officer, Polymun Scientific
• Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
• Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
• Kevin Daley, Director Pharmaceuticals, Novasep
• Mark Wright, Site Head, Grangemouth, Piramal Healthcare
• Nicolas Grandchamp, R&D Leader, GEG Tech
• Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
• Sebastian Schuck, Head of Business Development, Wacker Biotech
• Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
• Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
• Tim Oldham, Chief Executive Officer, Cell Therapies
Key companies covered in the report
• 3P Biopharmaceuticals
• Abzena
• Albany Molecular Research
• BioVectra
• BioXcellence (Boehringer Ingelheim)
• Celonic
• Charles River Laboratories
• ChemPartner
• Cobra Biologics
• CordenPharma
• Cytovance Biologics
• GE Healthcare
• Goodwin Biotechnology
• Grand River Aseptic Manufacturing
• IDT Biologika
• KBI BioPharma
• Kemwell Biopharma
• LFB Biomanufacturing
• Meridian Life Science
• Patheon
• Pfizer CentreOne
• PX'Therapeutics
• Samsung BioLogics
• Sanofi, CEPiA
• Thermo Fisher Scientific
• Vetter Pharma International
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/250/request-sample.html